Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: The effects of pimobendan on chronic heart failure study (EPOCH study)

Circulation Journal

Volumn 66, Issue 2, 2002, Pages 149-157

  Kato, K ^a   Iizuka, M ^a   Yazaki, Y ^a,a   Sasayama, Shigetake ^a   Nakashima, M ^a   Ohashi, Y ^a   Izumi, T ^a   Hori, M ^a   Matsuzaki, M ^a   Asanoi, H ^a   Taniguchi, K ^a   Katagiri, T ^a   Ito, H ^a   Hayashi, H ^a   Kitabatake, A ^a   Shirato, K ^a   Takeshita, A ^a   Kimata, S ^a   Koya, T ^a   Kato, N ^a   Matsuo, N ^a   Kanda, K ^a   Okada, H ^a   Tomita, K ^a   Sugawara, T ^a   Takechi, S ^a   Shogase, T ^a   Sato, H ^a   Murasaki, T ^a   Yamada, Y ^a   Segawa, I ^a   Nunokawa, T ^a   Sugawara, S ^a   Odakura, H ^a   Sukegawa, H ^a   Nozaki, N ^a   Nitobe, J ^a   Takeda, H ^a   Tomoike, H ^a   Yamaguchi, S ^a   Araki, T ^a   Goto, T ^a   Oguma, M ^a   Honma, K ^a   Matsui, M ^a   Maezawa, H ^a   Shimada, K ^a   Ikeda, U ^a   Oshima, S ^a   Adachi, H ^a   Hoshizaki, H ^a   Toyama, T ^a   Omata, M ^a   Momomura, S ^a   Sugiura, S ^a   Aoyagi, A ^a   Yokoyama, I ^a   Geshi, E ^a   Nagayama, M ^a   Akatsuka, N ^a   Okazaki, O ^a   Izumo, K ^a   Ogawa, S ^a   Mitamura, H ^a   Yoshikawa, T ^a   Mochizuki, S ^a   Ishiki, M ^a   Motomiya, T ^a   Yanase, O ^a   Ueda, S ^a   Kasanuki, H ^a   Kawana, M ^a   Takahashi, T ^a   Negishi, K ^a   Shiraki, H ^a   Ochiai, H ^a   Kimura, K ^a   Endo, T ^a   Yoshii, Y ^a   Sawada, R ^a   Miyazaki, N ^a   Iwata, A ^a   Hasegawa, T ^a   Hayashi, M ^a   Kurokawa, S ^a   Shimizu, M ^a   Sasaoka, T ^a   Takeyama, Y ^a   Tsutsumi, T ^a   Kondo, M ^a   Aizawa, Y ^a   Kodama, M ^a   Okura, Y ^a   Fujita, S ^a   Tsuda, T ^a   Watanabe, K ^a   Funazaki, T ^a   Tamura, Y ^a   more..

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Chronic heart failure; Inotropic drugs; Morbidity; Physical activity; Pimobendan

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PIMOBENDAN; RADIOISOTOPE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIA; CARDIOTONIC AGENTS; CHRONIC DISEASE; FEMALE; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PYRIDAZINES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0036234691     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.66.149     Document Type: Article

References (50)

1. The development of positive inotropic agents for chronic heart failure: How have we gone astray?
2. The epidemiology of heart failure: The Framingham Study
3. What do the newer inotropic drugs have to offer?
4. 2+ activation and the inotropic effect of pimobendan: Comparison with milrinone
5. Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate
6. New inotropic concepts: Rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors
7. Reversal of phosphate induced decreases in force by the benzimidazole pyridazinone, UD-CG212 CL, in myofilaments from human ventricle
8. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UDCG 212 in patients with congestive heart failure after single and repeated oral dosing
9. Pimobendane (UD-CG 115 B S) in the treatment of severe congestive heart failure: An acute haemodynamic cross-over and double-blind study with two different doses
10. Pimobendane (UD-CG 115 BS) in chronic congestive heart failure: Short-term and one-month effects of a new inotropic vasodilating agent
11. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure
12. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: Results of a multicenter trial
13. Longterm efficacy and safety of pimobendan in moderate heart failure: A double-blind parallel 6-month comparison with enalapril
14. Clinical efficacy and safety of pimobendan in treatment of heart failure: Experience in Japan
15. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial
16. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure
17. Stability of human atrial natriuretic peptide in blood samples
18. Assessment of left ventricular ejection and volumes by real-time, two-dimensional echocardiography: A comparison of cineangiographic and radionuclide techniques
19. Comparative value of eight M-mode echocardiographic formulas for determining left ventricular stroke volume: A correlative study with thermodilution and left ventricular single-plane cineangiography
20. Accurate measurment of left ventricular ejection fraction by three-dimensional echocardiography. A comparison with radionuclide angiography
21. Evaluation of functional capacity of patients with congestive heart failure
22. Effects of vesnarinone on morbidity and mortality in patients with heart failure
23. Tables of the number of patients required in clinical trials using the logrank test
24. Effect of oral milrinone on mortality in severe chronic heart failure
25. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
26. Hemodynamic characteristic during treadmill and bicycle exercise in chronic heart failure: Mechanism for different responses of peak oxygen uptake
27. Prognostic significance of cardiopulmonary exercise testing for 10-year survival in patients with mild to moderate heart failure
28. The time from anaerobic threshold (AT) to respiratory compensation point reflects the rate of aerobic and anaerobic metabolism after the AT in chronic heart failure patients
29. Assessment of quality of life as observed from the baseline data of the studies of left ventricular dysfunction (SOLVD) trial quality-of-life substudy
30. Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death
31. Calcium-sensitivity modulation of cardiac myofibrillar proteins
32. Mechanoenergetic effect of pimobendan in failing dog hearts
33. Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033
34. Will calcium sensitizers play a role in the treatment of heart failure?
35. Inodilator therapy for heart failure. Early, late, or not at all?
36. Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy
37. Interleukin I and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness
38. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo
39. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
40. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart
41. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte
42. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
43. Increased circulating cytokines in patients with myocarditis and cardiomyopathy
44. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure
45. Circulating interleukin-6 in severe heart failure
46. New insights into the pathophysiological role for cytokines in heart failure
47. Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages
48. Differential modulation of cytokine production by drugs: Implications for therapy in heart failure
49. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis
50. Pimobendan inhibits the activation of transcription factor NF-κB: A mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase